107 related articles for article (PubMed ID: 21215610)
21. Molecule of the month. Sorafenib.
Drug News Perspect; 2006 Mar; 19(2):119. PubMed ID: 16628266
[No Abstract] [Full Text] [Related]
22. Transient perforating folliculitis induced by sorafenib.
Minami-Hori M; Ishida-Yamamoto A; Komatsu S; Iiduka H
J Dermatol; 2010 Sep; 37(9):833-4. PubMed ID: 20883372
[No Abstract] [Full Text] [Related]
23. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
Bukowski RM; Stadler WM; McDermott DF; Dutcher JP; Knox JJ; Miller WH; Hainsworth JD; Henderson CA; Hajdenberg J; Kindwall-Keller TL; Ernstoff MS; Drabkin HA; Curti BD; Chu L; Ryan CW; Hotte SJ; Xia C; Cupit L; Figlin RA
Oncology; 2010; 78(5-6):340-7. PubMed ID: 20733337
[TBL] [Abstract][Full Text] [Related]
24. Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney.
Ansari J; Fatima A; Chaudhri S; Bhatt RI; Wallace M; James ND
Onkologie; 2009 Feb; 32(1-2):44-6. PubMed ID: 19209019
[TBL] [Abstract][Full Text] [Related]
25. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
Akaza H; Tsukamoto T; Murai M; Nakajima K; Naito S
Jpn J Clin Oncol; 2007 Oct; 37(10):755-62. PubMed ID: 17951335
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma.
Eng FC; Easson AM; Szentgyorgyi E; Knox JJ
Eur J Surg Oncol; 2009 Feb; 35(2):219-21. PubMed ID: 17976949
[No Abstract] [Full Text] [Related]
27. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET.
Hutson TE; Bellmunt J; Porta C; Szczylik C; Staehler M; Nadel A; Anderson S; Bukowski R; Eisen T; Escudier B;
Eur J Cancer; 2010 Sep; 46(13):2432-40. PubMed ID: 20656473
[TBL] [Abstract][Full Text] [Related]
28. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
Ratain MJ; Eisen T; Stadler WM; Flaherty KT; Kaye SB; Rosner GL; Gore M; Desai AA; Patnaik A; Xiong HQ; Rowinsky E; Abbruzzese JL; Xia C; Simantov R; Schwartz B; O'Dwyer PJ
J Clin Oncol; 2006 Jun; 24(16):2505-12. PubMed ID: 16636341
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib in renal cell carcinoma.
Flaherty KT
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):747s-752s. PubMed ID: 17255304
[TBL] [Abstract][Full Text] [Related]
30. [Nexavar clinical registry].
Büchler T
Klin Onkol; 2010; 23(4):269-70. PubMed ID: 20806826
[No Abstract] [Full Text] [Related]
31. CD4+CD25highFOXP3+ regulatory T cells in peripheral blood are primarily of effector memory phenotype.
Beyer M; Schultze JL
J Clin Oncol; 2007 Jun; 25(18):2628-30; author reply 2630-2. PubMed ID: 17577047
[No Abstract] [Full Text] [Related]
32. Immunological heterogeneity of the RCC microenvironment: do targeted therapies influence immune response?
Bex A; Etto T; Vyth-Dreese F; Blank C; Griffioen AW
Curr Oncol Rep; 2012 Jun; 14(3):230-9. PubMed ID: 22362358
[TBL] [Abstract][Full Text] [Related]
33. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.
Choueiri TK; Fishman MN; Escudier B; McDermott DF; Drake CG; Kluger H; Stadler WM; Perez-Gracia JL; McNeel DG; Curti B; Harrison MR; Plimack ER; Appleman L; Fong L; Albiges L; Cohen L; Young TC; Chasalow SD; Ross-Macdonald P; Srivastava S; Jure-Kunkel M; Kurland JF; Simon JS; Sznol M
Clin Cancer Res; 2016 Nov; 22(22):5461-5471. PubMed ID: 27169994
[TBL] [Abstract][Full Text] [Related]
34. [ I.Renal cell carcinoma].
Tomita Y
Gan To Kagaku Ryoho; 2014 Jan; 41(1):38-41. PubMed ID: 24796020
[No Abstract] [Full Text] [Related]
35. Inhaled IL-2 induces systemic immunomodulation in patients with renal cell carcinoma and lung metastasis.
Diaz D; Chara L; Chevarria J; Carballido J; Esteban E; Navas V; Monserrat J; Prieto A; de la Hera A; Alvarez-Mon M
Cancer Immunol Immunother; 2009 Feb; 58(2):235-45. PubMed ID: 18592236
[TBL] [Abstract][Full Text] [Related]
36. Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma.
Considine B; Hurwitz ME
Curr Oncol Rep; 2019 Mar; 21(4):34. PubMed ID: 30848378
[TBL] [Abstract][Full Text] [Related]
37. The Past, Present and Future of Immunotherapy for Metastatic Renal Cell Carcinoma.
Chang AJ; Zhao L; Zhu Z; Boulanger K; Xiao H; Wakefield MR; Bai Q; Fang Y
Anticancer Res; 2019 Jun; 39(6):2683-2687. PubMed ID: 31177102
[TBL] [Abstract][Full Text] [Related]
38. [Molecular Concepts of Immunomodulation for the Treatment of Metastatic Renal Cell Carcinomas: Where are We Now?].
Goebell PJ; Bedke J
Aktuelle Urol; 2015 Nov; 46(6):473-80. PubMed ID: 26488922
[TBL] [Abstract][Full Text] [Related]
39. Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview.
Lamers CH; Klaver Y; Gratama JW; Sleijfer S; Debets R
Biochem Soc Trans; 2016 Jun; 44(3):951-9. PubMed ID: 27284065
[TBL] [Abstract][Full Text] [Related]
40. [Can the immune system target cancer?].
Olweus J; Kolstad A
Tidsskr Nor Laegeforen; 2012 Apr; 132(7):784-5. PubMed ID: 22511078
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]